A high-fat and cholesterol diet causes fatty liver in guinea pigs. The role of iron and oxidative damage

References

• Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci 2011;48:97–113.
   PubMed Web of Science ®Google Scholar
• Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab 2008;93:S74–80.
   PubMed Web of Science ®Google Scholar
• O’Brien J, Powell LW. Non-alcoholic fatty liver disease: is iron relevant?Hepatol Int 2012;6:332–341.
   PubMedGoogle Scholar
• Wouters K, van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, Lutjohann D, et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008;48: 474–486.
   PubMed Web of Science ®Google Scholar
• Subramanian S, Goodspeed L, Wang S, Kim J, Zeng L, Ioannou GN, et al. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J Lipid Res 2011;52:1626–1635.
   PubMed Web of Science ®Google Scholar
• Kratz M. Dietary cholesterol, atherosclerosis and coronary heart disease. Handb Exp Pharmacol 2005:195–213.
   Google Scholar
• Harris JR, Milton NG. Cholesterol in Alzheimer's disease and other amyloidogenic disorders. Subcell Biochem 2010;51: 47–75.
   PubMedGoogle Scholar
• Yasutake K, Nakamuta M, Shima Y, Ohyama A, Masuda K, Haruta N, et al. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol 2009;44:471–477.
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 2011;55:920–932.
   PubMed Web of Science ®Google Scholar
• Halliwell B, Gutteridge JMC. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 1984;219: 1–14.
   PubMed Web of Science ®Google Scholar
• Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103–1109.
   PubMed Web of Science ®Google Scholar
• George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311–318.
   PubMed Web of Science ®Google Scholar
• Sumida Y, Yoshikawa T, Okanoue T. Role of hepatic iron in non-alcoholic steatohepatitis. Hepatol Res 2009;39:213–222.
   PubMed Web of Science ®Google Scholar
• Graham RM, Chua AC, Carter KW, Delima RD, Johnstone D, Herbison CE, et al. Hepatic iron loading in mice increases cholesterol biosynthesis. Hepatology 2010;52:462–471.
   PubMedGoogle Scholar
• Morrow JD, Chen Y, Brame CJ, Yang J, Sanchez SC, Xu J, et al. The isoprostanes: unique prostaglandin-like products of free-radical-initiated lipid peroxidation. Drug Metab Rev 1999;31:117–139.
   PubMed Web of Science ®Google Scholar
• Halliwell B, Lee CY. Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. Antioxid Redox Signal 2010;13:145–156.
   PubMed Web of Science ®Google Scholar
• Tang SY, Whiteman M, Peng ZF, Jenner A, Yong EL, Halliwell B. Characterization of antioxidant and antiglycation properties and isolation of active ingredients from traditional Chinese medicines. Free Radic Biol Med 2004;36: 1575–1587.
   PubMed Web of Science ®Google Scholar
• Langford MP, Redens TB, Harris NR, Lee S, Jain SK, Reddy S, McVie R. Plasma levels of cell-free apoptotic DNA ladders and gamma-glutamyltranspeptidase (GGT) in diabetic children. Exp Biol Med (Maywood) 2007;232: 1160–1169.
   PubMed Web of Science ®Google Scholar
• Szasz G. A kinetic photometric method for serum gamma-glutamyl transpeptidase. Clin Chem 1969;15:124–136.
   PubMed Web of Science ®Google Scholar
• Riemer J, Hoepken HH, Czerwinska H, Robinson SR, Dringen R. Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. Anal Biochem 2004;331: 370–375.
   PubMed Web of Science ®Google Scholar
• Sinclair PR, Gorman N, Jacobs JM. Measurement of heme concentration. Curr Protoc Toxicol 2001;Chapter 8:Unit 8 3.
   Google Scholar
• Jenner A, Ren M, Rajendran R, Ning P, Huat BT, Watt F, Halliwell B. Zinc supplementation inhibits lipid peroxidation and the development of atherosclerosis in rabbits fed a high cholesterol diet. Free Radic Biol Med 2007;42:559–566.
   PubMed Web of Science ®Google Scholar
• Lee CY, Huang SH, Jenner AM, Halliwell B. Measurement of F2-isoprostanes, hydroxyeicosatetraenoic products, and oxysterols from a single plasma sample. Free Radic Biol Med 2008;44:1314–1322.
   PubMed Web of Science ®Google Scholar
• Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961;93:440–447.
   PubMed Web of Science ®Google Scholar
• Ye P, Cheah IK, Halliwell B. High fat diets and pathology in the guinea pig. Atherosclerosis or liver damage?Biochim Biophys Acta 2013;1832:355–364.
   PubMed Web of Science ®Google Scholar
• Cook RP, Thomson RO. Cholesterol metabolism. 3. Cholesterol metabolism in the guinea pig and rabbit. Biochem J 1951;49:72–77.
   PubMedGoogle Scholar
• Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356–1362.
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Manzini P, D’Antico S, Vanni E, Longo F, Leone N, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004;39:179–187.
   PubMed Web of Science ®Google Scholar
• Chevion M, Berenshtein E, Stadtman ER. Human studies related to protein oxidation: protein carbonyl content as a marker of damage. Free Radic Res 2000;33:S99–108.
   PubMed Web of Science ®Google Scholar
• Tsushima Y, Endo K. Spleen enlargement in patients with nonalcoholic fatty liver: correlation between degree of fatty infiltration in liver and size of spleen. Dig Dis Sci 2000;45: 196–200.
   PubMed Web of Science ®Google Scholar
• Fleming RE, Sly WS. Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci USA 2001;98: 8160–8162.
   PubMed Web of Science ®Google Scholar
• Andrews NC. Closing the iron gate. N Engl J Med 2012;366: 376–377.
   PubMed Web of Science ®Google Scholar
• Nagashima M, Kudo M, Chung H, Ishikawa E, Hagiwara S, Nakatani T, Dote K. Regulatory failure of serum prohepcidin levels in patients with hepatitis C. Hepatol Res 2006;36: 288–293.
   PubMedGoogle Scholar
• Fujita N, Sugimoto R, Motonishi S, Tomosugi N, Tanaka H, Takeo M, et al. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J Hepatol 2008;49:702–710.
   PubMed Web of Science ®Google Scholar
• Bridle K, Cheung TK, Murphy T, Walters M, Anderson G, Crawford DG, Fletcher LM. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res 2006;30: 106–112.
   PubMed Web of Science ®Google Scholar
• Potter BJ, Chapman RW, Nunes RM, Sorrentino D, Sherlock S. Transferrin metabolism in alcoholic liver disease. Hepatology 1985;5:714–721.
   PubMed Web of Science ®Google Scholar
• Bothwell TH, MacPhail AP. Hereditary hemochromatosis: etiologic, pathologic, and clinical aspects. Semin Hematol 1998;35:55–71.
   PubMed Web of Science ®Google Scholar
• Le Lan C, Loreal O, Cohen T, Ropert M, Glickstein H, Laine F, et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 2005;105:4527–4531.
   PubMed Web of Science ®Google Scholar
• Shin DY, Chung J, Joe Y, Pae HO, Chang KC, Cho GJ, et al. Pretreatment with CO-releasing molecules suppresses hepcidin expression during inflammation and endoplasmic reticulum stress through inhibition of the STAT3 and CREBH pathways. Blood 2012;119:2523–2532.
   PubMedGoogle Scholar
• Otogawa K, Kinoshita K, Fujii H, Sakabe M, Shiga R, Nakatani K, et al. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis. Am J Pathol 2007;170:967–980.
   PubMed Web of Science ®Google Scholar
• Aigner E, Theurl I, Theurl M, Lederer D, Haufe H, Dietze O, et al. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr 2008;87: 1374–1383.
   PubMedGoogle Scholar
• Hoffman KE, Yanelli K, Bridges KR. Ascorbic acid and iron metabolism: alterations in lysosomal function. Am J Clin Nutr 1991;54:1188S–1192S.
   PubMedGoogle Scholar
• O’Connell M, Halliwell B, Moorhouse CP, Aruoma OI, Baum H, Peters TJ. Formation of hydroxyl radicals in the presence of ferritin and haemosiderin. Is haemosiderin formation a biological protective mechanism?Biochem J 1986;234: 727–731.
   PubMed Web of Science ®Google Scholar
• Lecube A, Hernandez C, Simo R. Glucose abnormalities in non-alcoholic fatty liver disease and chronic hepatitis C virus infection: the role of iron overload. Diabetes Metab Res Rev 2009;25:403–410.
   PubMedGoogle Scholar
• Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002;122: 931–939.
   PubMed Web of Science ®Google Scholar
• Davis RJ, Corvera S, Czech MP. Insulin stimulates cellular iron uptake and causes the redistribution of intracellular transferrin receptors to the plasma membrane. J Biol Chem 1986;261:8708–8711.
   PubMed Web of Science ®Google Scholar
• Tsuchiya H, Ebata Y, Sakabe T, Hama S, Kogure K, Shiota G. High-fat, high-fructose diet induces hepatic iron overload via a hepcidin-independent mechanism prior to the onset of liver steatosis and insulin resistance in mice. Metabolism 2013;62:62–69.
   PubMed Web of Science ®Google Scholar